RANCHO CORDOVA, Calif.,
Jan. 10, 2022 /PRNewswire/
-- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market
leader in automated cell processing tools and services in the cell
and gene therapy field, today announced that Chief Financial
Officer, Jeff Cauble, will present a
company overview at the H.C. Wainwright BioConnect Virtual
Conference taking place January 10-13,
2022.
The on-demand presentation is available for viewing on
ThermoGenesis' website at:
https://thermogenesis.com/investors/news-and-events/events-webcasts/ and
will be archived for a period of 90 days following the event.
About ThermoGenesis Holdings, Inc.
ThermoGenesis
Holdings, Inc. develops, commercializes, and markets a range of
automated technologies for CAR-T and other cell-based therapies.
The Company currently markets a full suite of solutions for
automated clinical biobanking, point-of-care applications, and
automation for immuno-oncology, including its semi-automated,
functionally-closed CAR-TXpress™ platform, which streamlines
the manufacturing process for the emerging CAR-T immunotherapy
market. For more information about ThermoGenesis, please
visit: www.thermogenesis.com.
Company Contact:
Wendy
Samford
916-858-5191
ir@ThermoGenesis.com
Investor Contact:
Paula Schwartz, Rx
Communications
917-322-2216
pschwartz@rxir.com
View original
content:https://www.prnewswire.com/news-releases/thermogenesis-holdings-to-present-at-the-hc-wainwright-bioconnect-virtual-conference-301456955.html
SOURCE ThermoGenesis Holdings, Inc.